DT Investment Partners’s Moderna MRNA Stock Holding History

DT Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-44	Closed	-$2.94K	–	601
2024 Q3	$2.94K	Buy	+44	New	+$4.04K	﹤0.01%	576

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

DT Investment Partners's MRNA Position: Q4 2024 in Review

DT Investment Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 44 shares — an estimated $2.94K sold.

DT Investment Partners first reported a position in MRNA in Q3 2024 and held it in 1 quarter. The position peaked at $2.94K in Q3 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

DT Investment Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
DT Investment Partners sold 44 Moderna shares in Q4 2024, an estimated $2.94K.
DT Investment Partners first reported a position in Moderna in Q3 2024 and held it in 1 quarter.
DT Investment Partners's Moderna position peaked at $2.94K in Q3 2024.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on DT Investment Partners's 13F filing for Q4 2024, filed 30 Jan 2025.